Patents by Inventor Joseph Pidala

Joseph Pidala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AURORA KINASE AND JANUS KINASE INHIBITORS FOR PREVENTION OF GRAFT VERSUS HOST DISEASE
    Publication number: 20230150948
    Abstract: Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V.
    Type: Application
    Filed: January 19, 2023
    Publication date: May 18, 2023
    Inventors: Brian Betts, Said M. Sebti, Harshani Lawrence, Nicholas Lawrence, Claudio Anasetti, Joseph Pidala
  • AURORA KINASE AND JANUS KINASE INHIBITORS FOR PREVENTION OF GRAFT VERSUS HOST DISEASE
    Publication number: 20220281828
    Abstract: Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 8, 2022
    Inventors: Brian Betts, Said M. Sebti, Harshani Lawrence, Nicholas Lawrence, Claudio Anasetti, Joseph Pidala
  • Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
    Patent number: 11203576
    Abstract: Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: December 21, 2021
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Brian Betts, Said M. Sebti, Harshani Lawrence, Nicholas Lawrence, Claudio Anasetti, Joseph Pidala
  • AURORA KINASE AND JANUS KINASE INHIBITORS FOR PREVENTION OF GRAFT VERSUS HOST DISEASE
    Publication number: 20190127335
    Abstract: Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V.
    Type: Application
    Filed: March 13, 2017
    Publication date: May 2, 2019
    Inventors: Brian Betts, Said Sebti, Harshani Lawrence, Nicholas Lawrence, Claudio Anasetti, Joseph Pidala